Pulmonary arterial hypertension (PAH) is a rare, progressive disease characterised by elevated pulmonary arterial pressure and vascular resistance that eventually leads to right ventricular failure and death[1]
Early identification and intervention are key to changing the course of the disease[2]
PAH is a severe and often fatal complication of CTD:[3]
PAH is a leading cause of death in patients with SSc, accounting for >50% of deaths in SSc-PAH patients[6]
Adapted from Badesch et al. 2010[7]
Component not published? componentType is undefined.
Medical Scientific Liaison Pulmonary
Hypertension NL
+31 6 1238 17 11
mkruk1@its.jnj.com
Medical Advisor Pulmonary
Hypertension NL
+31 6 53 72 73 03
rjansse9@its.jnj.com
Vous avez une question à nous poser ou vous n’avez pas trouvé ce que vous recherchiez ? Contactez-nous, nous serons ravis de vous aider.
Découvrez le portefeuille des produits Janssen et les résumés des caractéristiques des produits correspondants.
Découvrez les animations 3D interactives de l’anatomie humaine et de différentes pathologies.
ALT, alanine aminotransferase; AST, aspartate aminotransferase;CHD, congenital heart disease; CI, confidence interval; CTD, connective tissue disease; ERA, endothelin receptor antagonist; ERS, European Respiratory Society; ESC, European Society of Cardiology; HIV, human immunodeficiency virus; HPAH, heritable pulmonary arterial hypertension; HR, hazard ratio; IPAH, idiopathic pulmonary arterial hypertension; LFT, liver function test; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PoPH, portopulmonary hypertension; RHC, right heart catheterisation; SSc, systemic sclerosis; TRV, tricuspid regurgitation velocity; ULN, upper limit of normal; 6MWD, six-minute walk distance